Compare American Financial Group Inc (AFG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Illumina, Inc. — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.97B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 2.4× American Financial Group Inc's market cap, and American Financial Group Inc pays a 2.44% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AFG | ILMN | |
|---|---|---|
Market Cap | $11.97B | $29.12B |
Sector | Financials | Health |
52-Week High | $148.71 | $205.10 |
52-Week Low | $124.18 | $91.00 |
Enterprise Value | $12.35B | $30.48B |
Dividend Yield | 2.44% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
